Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Non-Current Debt (2016 - 2017)

Protalix BioTherapeutics (PLX) has 6 years of Non-Current Debt data on record, last reported at $4.3 million in Q3 2017.

  • For Q3 2017, Non-Current Debt changed 0.0% year-over-year to $4.3 million; the TTM value through Sep 2017 reached $4.3 million, changed 0.0%, while the annual FY2016 figure was $4.3 million, 0.0% changed from the prior year.
  • Non-Current Debt reached $4.3 million in Q3 2017 per PLX's latest filing, roughly flat from $4.3 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $4.3 million in Q4 2015 and bottomed at $376000.0 in Q2 2013.
  • Average Non-Current Debt over 4 years is $3.6 million, with a median of $4.3 million recorded in 2015.
  • Peak YoY movement for Non-Current Debt: plummeted 91.97% in 2013, then changed 0.0% in 2016.
  • A 4-year view of Non-Current Debt shows it stood at $2.4 million in 2013, then soared by 81.4% to $4.3 million in 2015, then changed by 0.0% to $4.3 million in 2016, then changed by 0.0% to $4.3 million in 2017.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $4.3 million in Q3 2017, $4.3 million in Q2 2017, and $4.3 million in Q1 2017.